Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 34Lung Neoplasms 9Neoplasms 6Neoplasm Metastasis 5Carcinoma 5Pancreatic Neoplasms 2Ovarian Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thoracic Neoplasms 1Stage IB-IIIA Non-small Cell Lung Carcinoma 1Skin Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Prostatic Neoplasms 1Noonan Syndrome 1Non Small Cell Lung Cancer Metastatic 1Neoplasms, Squamous Cell 1Neoplasms by Site 1NSCLC 1Multiple Myeloma 1Lymphoma 1Lung Diseases 1Locally Advanced or Metastatic EGFR T790M+ NSCLC 1Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer 1Hematologic Neoplasms 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

Carboplatin 25Bevacizumab 18Paclitaxel 17Pemetrexed 16Erlotinib Hydrochloride 14Radiotherapy 12Docetaxel 9Gemcitabine 7Cisplatin 6ceritinib 5Taxes 5Cetuximab 5pembrolizumab 3pegfilgrastim 3capmatinib 3Surgical Procedures, Operative 3Radiosurgery 3Metformin 3Gefitinib 3Cyclophosphamide 3Thalidomide 2Sorafenib 2Radiotherapy, Conformal 2Nivolumab 2Immunoglobulin G 2Filgrastim 2Disulfides 2Albumin-Bound Paclitaxel 25-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide 2veliparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Adenocarcinoma of Lung × osimertinib × Clear all
NCT02759835 2024-06-07

Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
37 enrolled 23 charts
Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡